Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Background The role of cytoreductive surgery in relapsed ovarian cancer is not clearly
defined. Therefore, patient selection remains arbitrary and depends on the center's …
defined. Therefore, patient selection remains arbitrary and depends on the center's …
Adoptive Transfer of Tumor Cytotoxic Macrophages Generated in Vitro from Circulating Blood Monocytes: A New Approach to Cancer Immunotherapy
R Andreesen, C Scheibenbogen, W Brugger, S Krause… - Cancer research, 1990 - AACR
Cells of the macrophage lineage are considered to be of special importance in the defense
of the host against tumor development and spread. Immunotherapeutic strategies to …
of the host against tumor development and spread. Immunotherapeutic strategies to …
A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection
WJ Tian, DS Chi, J Sehouli, CG Tropé, R Jiang… - Annals of surgical …, 2012 - Springer
Background To develop a risk model for predicting complete secondary cytoreductive
surgery (SCR) in patients with recurrent ovarian cancer. Methods Individual data of 1075 …
surgery (SCR) in patients with recurrent ovarian cancer. Methods Individual data of 1075 …
Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern …
J Sehouli, D Stengel, P Harter, C Kurzeder… - Journal of Clinical …, 2011 - ascopubs.org
Purpose Weekly administration of topotecan (Tw) is less toxic and widely considered a
better treatment option than conventional 5-day therapy (Tc) in women with platinum …
better treatment option than conventional 5-day therapy (Tc) in women with platinum …
Diagnosis of breast cancer with infrared spectroscopy from serum samples
J Backhaus, R Mueller, N Formanski, N Szlama… - Vibrational …, 2010 - Elsevier
The detection of breast cancer has a special value in the diagnosis of cancer diseases. It is
the most frequent type of cancer among women's. We have developed a simple and rapid …
the most frequent type of cancer among women's. We have developed a simple and rapid …
[PDF][PDF] First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2–positive metastatic breast …
M Untch, M Muscholl, S Tjulandin, W Jonat… - Journal of clinical …, 2010 - researchgate.net
Purpose A high incidence of congestive heart failure (CHF) has been observed in patients
with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and …
with metastatic breast cancer (MBC) receiving doxorubicin-based chemotherapy and …
Effect of celecoxib vs placebo as adjuvant therapy on disease-free survival among patients with breast cancer: the REACT randomized clinical trial
RC Coombes, H Tovey, L Kilburn, J Mansi… - JAMA …, 2021 - jamanetwork.com
Importance Patients with breast cancer remain at risk of relapse after adjuvant therapy.
Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but …
Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but …
Course, patterns, and risk-factors for chemotherapy-induced emesis in cisplatin-pretreated patients: a study with ondansetron
A Du Bois, HG Meerpohl, FGM Kommoss… - European journal of …, 1992 - Elsevier
Vomiting and nausea are the most distressing side-effects of cancer chemotherapy. With
standard antiemetic regimens (eg metoclopramide based combinations) sufficient antiemetic …
standard antiemetic regimens (eg metoclopramide based combinations) sufficient antiemetic …
Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics.
H Maier-Lenz, B Hauns, B Haering, J Koetting… - Seminars in …, 1997 - europepmc.org
Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) is one of the most important
new drugs used in the treatment of solid tumors. Use of paclitaxel, however, is associated …
new drugs used in the treatment of solid tumors. Use of paclitaxel, however, is associated …
Studies on the activation of mouse bone marrow‐derived macrophages by the macrophage cytotoxicity factor (MCF)
HG Meerpohl, ML Lohmann‐Matthes… - European journal of …, 1976 - Wiley Online Library
The capacity of bone marrow‐derived macrophages to be rendered cytotoxic by
macrophage cytotoxicity factor (MCF) at different stages of maturation was tested. Under in …
macrophage cytotoxicity factor (MCF) at different stages of maturation was tested. Under in …